Recent Finacing
Recent Raise
Galimedix develops drugs targeting toxic β‑amyloid, advancing GAL‑101 as eye drops and oral for dry AMD and glaucoma, plus GAL‑201 preclinical for Alzheimer’s; based in US, Europe, Israel.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at Galimedix Therapeutics.
